Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune...
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune...
In an exciting update, Prescient Therapeutics (ASX: PTX) has announced that it has been granted a key...
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke outlines the company's oncology treatment vision in a new...
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a...
Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M.
In an upbeat development, clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has rolled out a second cell...
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor...
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.